This was indicated by not only a faster reduction in tumour size upon aPD-1 + erlotinib therapy compared to EGFR inhibition alone, but also by tumours remaining in a partial response (PR) state until the end of the experiments, in contrast to the erlotinib group (Figure 5A). The gene discussed is EGFR; the disease is neoplasm.